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Abstract
Whooping cough remains a health problem despite high vaccination coverage. It has been recommended that
development of new strategies provide long-lasting immunity. The aim of this work was to evaluate the potential
of proteoliposomes (PL) extracted from Bordetella pertussis as a vaccine candidate against whooping cough. The
size of the B. pertussis PL was estimated to be 96.7±50.9 nm by Scanning Correlation Spectroscopy and the
polydispersity index was 0.268. Western blots using monoclonal antibodies revealed the presence of pertussis toxin,
pertactin, and fimbriae 3. The Limulus Amebocyte Lisate (LAL) assay showed endotoxin levels lower than those
reported for whole cell pertussis licensed vaccines, while the Pyrogen Test indicated 75 ng/mL/Kg. The PL showed
high protection capacity in mouse challenge models. There was 89.7% survival in the intracerebral challenge and
total reduction of the number of CFU in the intranasal challenge. No significant differences (p>0.05) were observed
between mice immunized with B. pertussis PL and the Cuban DTwP vaccine, whichever challenge model used.
These results encouraged us to continue the development of the B. pertussis PL as a component of a new
combined vaccine formulated with tetanus and diphtheria toxoids or as a booster dose for adolescents and adults.
Introduction
Whooping cough remains an important cause of public
health concern worldwide. Data from WHO revealed that
more than 16 million cases and about 195 000 deaths were
reported in 2008 [1]. Despite high vaccination coverage
with whole-cell (wP) or acellular (aP) vaccines, pertussis is
still prevalent, probably in part, as a result of waning immu-
nity and for that reason new vaccine strategies, able to pro-
vide long-lasting immunity have been recommended [2].
Bacterial-derived proteoliposomes (PL) are nanoparticulate
vesicular structures that contain proteins, lipids and native
lipopolysaccharide (LPS). To date, only a few licensed PL-
based vaccines are available. One of them is VA-MEN-
GOC-BC®, a vaccine composed of PL obtained from the
outer membrane of Neisseria meningitidis serogroup B.
This PL has been shown to have high efficacy in controlling
meningococcal disease [3] and has also exhibited potent
adjuvant activity when used with other vaccine antigens not
only in its native form, but in cochleate form too [4]. Thus,
a PL derived from B. pertussis could be a good approach
for a new candidate vaccine against whooping cough.
Materials and methods
Cellular pellets of B. pertussis strain 165 grown at indus-
trial scale, inactivated with formalin 0.1% through 48-56
hours, were homogenized with 30 mM Tris buffer, con-
taining 2mM EDTA, pH 8.5 at a ratio of 100-200mg/
mL. Sodium deoxycholate (Fluka, Switzerland) was
added at a ratio of 0.1-1 mL/g of biomass. The mixture
was incubated for 1 hour and centrifuged at 33000g for
15 min. All supernatants were collected, subjected to a
sequence of diafiltration processes and filtered using a* Correspondence: sfernandez@finlay.edu.cu
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Sartorius Minisart-plus unit of 0.2 µm. Particle size PL
was determined by Photon Correlation Spectroscopy
(PCS) (Beckman Coulter, Hialeach, FL, US). SDS-PAGE
(polyacrylamide 13%) followed by a R250 Blue Coomas-
sie or silver stain for LPS [5,6] was carried out using a
low molecular weight marker (Amersham, UK). Western
blot assays [7] were carried out using monoclonal anti-
bodies (Mabs) against pertussis toxin (PT), pertactin
(PRN) and fimbriae 3 (FIM3) (NIBSC, UK). The biologi-
cal activity of the endotoxin present in the PL was
determined by Limulus Amebocyte Lisate (LAL) [8] and
by a Total Pyrogen Test in rabbits [9] at 10, 25, 50, 75
ng/mL concentrations of protein. Intracerebral challenge
assays were carried out in 4-6 weeks old, 16-18 g, female
OF1 mice (CENPALAB, Cuba) injected intraperitoneally
with one dose of 0.5 mL of 60 µg of PL and aluminum
hydroxide (1mg/mL), DTwP vaccine (Finlay Institute)
prepared at 8 Ul/mL or placebo. Intracerebral challenge
with B. pertussis 18323 (100-1000 DL50) was performed
2 weeks post immunization. All mice were observed for
14 days after the challenge and daily mortality was
registered. For the intranasal challenge assay, BALB/c
mice (female, 3-4 weeks, 12-14 g, CENPALAB, Cuba)
were immunized subcutaneously with 2 doses, 125 µL
separated by a three-week interval. Each dose consisted of
20 µg of PL and 0.25 mg of aluminum hydroxide. A group
of mice was immunized with 125 µL of DTwP vaccine
(Finlay Institute) while another group received 125 µL of
PBS and aluminum hydroxide as placebo. The intranasal
challenge and lung extraction was performed following the
procedure described by Guiso et al. [10]. Results were
expressed as the average Log10 of the CFU/g of lung
for each group of mice at each extraction time after
challenge.
Statistical analysis
The Wilson approximate method and software R 2.10.0
[11] were used to calculate the confidence intervals. The
arithmetic means ± standard deviation for Log10 CFU/
lung were also calculated. The comparison of arithmetic
means of the groups was carried out by an analysis of sim-
ple variance (Statistic kit, Statgraphics Plus 5.0).
Figure 1 B. pertussis PL composition analysis; Panel A, SDS-PAGE (polyacrylamide 13 %) followed by R250 Blue Coomasie stain. Lane 1: Low
molecular weight markers (97-14.4 kDa), Lane 2: B. pertussis PL. Panel B, SDS-PAGE of B. pertussis PL (polyacrylamide 13 %) followed by a
LPS-specific silver stain. Panel C, Western blot of B. pertussis PL using Mabs or serum vs relevant antigens; Lane 1: Low molecular weight markers
(97-14.4 kDa), Lane 2: PT anti serum (97/572), Lane 3: FIM 3 Mab (04/156), Lane 4: PRN anti serum (97/558).
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Results and discussion
Sodium deoxycholate was used to extract proteolipo-
somes from the outer membranes of inactivated cells of
B. pertussis strain 165. The size of the PL was estimated
to be 96.7 ± 50.9 nm with a polydispersity index of
0.268. SDS-PAGE (Figure 1 panels A and B) suggests
the presence of molecules such as LPS and outer mem-
brane proteins. Western blot assays using Mabs showed
the presence of PT, FIM 3 and PRN (Figure 1 panel C),
all of them are protective antigens present in acellular
vaccines [12]. Proteomic and western blot studies with
other Mabs are planed to completely elucidate the anti-
genic composition of B. pertussis PL. The biological
activity of the endotoxin in PL was evaluated by the
LAL method and showed a value of 4 960 EU/dose or 9
920 EU/mL. The endotoxic activity was higher than
those reported for licensed aP vaccines (38 – 1 390 EU/
mL), but lower than those reported for some licensed wP
vaccines (11 400 – 181 100 EU/mL) [13], and similar to the
meningococcal vaccine MenB (≤ 20 000 EU/mL) which
consists of outer membrane vesicles [14]. In addition, the
PL were non pyrogenic at concentrations less than or equal
to 75 ng/mL/Kg of weigh of rabbits, according to the Total
Pyrogen Test.
Mice immunized with both, the PL and DTwP vaccine,
showed high protection levels against intracerebral chal-
lenge [89.7% and 91.2 of survival, respectively (95% confi-
dence in the interval 76.4–95.9%)]. These values were
significantly different in relation to the placebo group
[12.1% of survival (95% confidence in the interval 4.8–
27.3%)] and there were no differences between them
(P<0.05). No mice died during the assay due to post-chal-
lenge trauma. Protective capacity induced by PL and
DTwP vaccine, was also estimated by intranasal challenge
(Table 1). Four days after challenge, no CFU were counted
in lungs of mice immunized with PL or DTwP vaccine.
Conversely, the number of CFU recovered from lungs of
mice belonging to the Placebo group, at 4 and 7 days, was
significantly (P<0.05) high compared with the other two
groups. Overall, these results clearly indicate the potential
of B. pertussis PL as a vaccine candidate against whooping
cough.
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